VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 83 filers reported holding VAXCYTE INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $277,229 | +10.6% | 5,438 | +8.3% | 0.01% | +16.7% |
| Q2 2023 | $250,699 | +68.1% | 5,020 | +26.2% | 0.01% | +50.0% |
| Q1 2023 | $149,095 | -29.8% | 3,978 | -10.2% | 0.01% | -20.0% |
| Q4 2022 | $212,466 | +177.2% | 4,431 | +38.7% | 0.01% | +150.0% |
| Q3 2022 | $76,656 | +10.3% | 3,194 | 0.0% | 0.00% | +33.3% |
| Q2 2022 | $69,501 | +7.6% | 3,194 | +19.4% | 0.00% | +50.0% |
| Q1 2022 | $64,577 | -76.2% | 2,674 | -76.6% | 0.00% | -50.0% |
| Q4 2021 | $271,610 | -6.2% | 11,417 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $289,649 | +12.7% | 11,417 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $256,997 | +52.1% | 11,417 | +33.4% | 0.00% | +33.3% |
| Q1 2021 | $168,981 | +17.8% | 8,556 | +58.5% | 0.00% | +50.0% |
| Q4 2020 | $143,398 | -46.2% | 5,397 | 0.0% | 0.00% | -60.0% |
| Q3 2020 | $266,504 | – | 5,397 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |